DK0624594T3 - Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel - Google Patents

Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel

Info

Publication number
DK0624594T3
DK0624594T3 DK94106845T DK94106845T DK0624594T3 DK 0624594 T3 DK0624594 T3 DK 0624594T3 DK 94106845 T DK94106845 T DK 94106845T DK 94106845 T DK94106845 T DK 94106845T DK 0624594 T3 DK0624594 T3 DK 0624594T3
Authority
DK
Denmark
Prior art keywords
compounds
processes
preparation
acid derivatives
bile acid
Prior art date
Application number
DK94106845T
Other languages
Danish (da)
English (en)
Inventor
Heiner Dr Glombik
Alfons Dr Enhsen
Werner Dr Dr Kramer
Guenther Dr Wess
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0624594T3 publication Critical patent/DK0624594T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94106845T 1993-05-08 1994-05-02 Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel DK0624594T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315439 1993-05-08

Publications (1)

Publication Number Publication Date
DK0624594T3 true DK0624594T3 (da) 1999-12-13

Family

ID=6487634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94106845T DK0624594T3 (da) 1993-05-08 1994-05-02 Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel

Country Status (18)

Country Link
US (1) US5610151A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0624594B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3424978B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100333151B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE183191T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU673419B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2123052C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ289209B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE59408602D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0624594T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2136677T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI942077A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3031541T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT67574A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL109580A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO304794B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ260471A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW289021B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160783T1 (de) * 1992-06-12 1997-12-15 Hoechst Ag Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel
TW289020B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
DE19845403B4 (de) * 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19849722A1 (de) * 1998-10-28 2000-05-04 Aventis Pharma Gmbh Substituierte Phenyl-alkenoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL143946A0 (en) * 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indications
CA2356607A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
CN1338945A (zh) * 1998-12-23 2002-03-06 G·D·瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆汁酸螯合剂组合
JP2002533410A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびフィブリン酸誘導体の組み合わせ
EP1140184B1 (en) * 1998-12-23 2003-06-04 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU2157500A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
AU779264B2 (en) * 1998-12-23 2005-01-13 G.D. Searle Llc Combinations for cardiovascular indications
DE19941764A1 (de) * 1999-09-02 2001-03-15 Aventis Pharma Gmbh Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente
JP4833471B2 (ja) * 1999-09-22 2011-12-07 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 胆汁酸との４−ベンジルアミノキノリン抱合体およびそれらのヘテロ類似体、それらの製造法、それらの化合物を含有する薬剤ならびにそれらの使用
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6624155B2 (en) * 2001-05-01 2003-09-23 Board Of Trustees Of The University Of Arkansas Hybrid cholinergic agents and compositions
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
BR0213501A (pt) * 2001-11-02 2004-08-24 Searle Llc Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
DE10259374A1 (de) * 2002-12-18 2004-07-08 Atto-Tec Gmbh Carboxamid-substituierte Farbstoffe für analytische Anwendungen
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7344701B2 (en) * 2004-02-03 2008-03-18 Biosearch Technologies, Inc. Xanthene dyes
CA2562151C (en) 2004-04-30 2016-09-06 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a c5-modified pyrimidine
US8391785B2 (en) * 2005-04-29 2013-03-05 Impinj, Inc. Interference rejection in RFID tags
JP4913561B2 (ja) * 2006-11-17 2012-04-11 株式会社リコー コロナ帯電装置及び画像形成装置
US20110294767A1 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
RU2591188C2 (ru) 2010-11-04 2016-07-10 Альбирео Аб Ингибиторы ibat для лечения заболеваний печени
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
WO2013063512A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
BR112014010228B1 (pt) 2011-10-28 2020-09-29 Lumena Pharmaceuticals Llc Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
EP2968230A2 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954926B2 (ja) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ 経口コレスチラミン製剤及びその使用
CA3011619C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
JP2018199648A (ja) * 2017-05-29 2018-12-20 五稜化薬株式会社 新規トランスポーター機能解析用蛍光物質
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
ES3011850T3 (en) 2018-06-20 2025-04-08 Albireo Ab Crystal modifications of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
PT3921028T (pt) 2019-02-06 2023-02-15 Albireo Ab Compostos de benzotiadiazepina e a sua utilização como moduladores de ácido biliar
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3129827A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
PT4069360T (pt) 2019-12-04 2024-03-06 Albireo Ab Compostos de benzotia(di)azepina e a sua utilização como moduladores de ácido biliar
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
KR102587117B1 (ko) 2020-10-09 2023-10-10 포리프라스틱 가부시키가이샤 폴리아세탈 수지 조성물 및 자동차 부품
JP7078687B2 (ja) 2020-10-09 2022-05-31 ポリプラスチックス株式会社 ポリアセタール樹脂組成物及び自動車部品
KR20230106651A (ko) 2020-11-12 2023-07-13 알비레오 에이비 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
CN119053330A (zh) 2022-04-22 2024-11-29 阿尔比里奥公司 皮下给药asbt抑制剂
JP2025524362A (ja) 2022-06-09 2025-07-30 アルビレオ・アクチボラグ 肝炎の処置
AU2023304672A1 (en) 2022-07-05 2025-01-02 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2023390975A1 (en) 2022-12-09 2025-06-05 Albireo Ab Asbt inhibitors in the treatment of renal diseases
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US417725A (en) * 1889-12-24 Coffin
US489423A (en) * 1893-01-03 Electric time-alarm
DE1119263B (de) * 1959-07-09 1961-12-14 Riedel De Haeen Ag Verfahren zur Herstellung neuer Sulfonylurethane
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US4217279A (en) * 1978-12-18 1980-08-12 Kaiser Emil T Synthesis of steroids
US4848349A (en) * 1987-04-29 1989-07-18 Sherman Igor A Substance and method for measuring hepatic blood flow
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
DK0489423T3 (da) * 1990-12-06 1997-04-14 Hoechst Ag Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelsen af disse forbindelser som lægemidler
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping

Also Published As

Publication number Publication date
DE59408602D1 (de) 1999-09-16
NO941680L (no) 1994-11-09
EP0624594A3 (de) 1996-05-01
NZ260471A (en) 1995-04-27
JP3424978B2 (ja) 2003-07-07
IL109580A (en) 1999-03-12
EP0624594B1 (de) 1999-08-11
NO304794B1 (no) 1999-02-15
TW289021B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-10-21
EP0624594A2 (de) 1994-11-17
US5610151A (en) 1997-03-11
JPH072891A (ja) 1995-01-06
FI942077L (fi) 1994-11-09
NO941680D0 (no) 1994-05-06
CZ289209B6 (cs) 2001-12-12
CA2123052A1 (en) 1994-11-09
FI942077A0 (fi) 1994-05-05
CZ113794A3 (en) 1994-11-16
FI942077A7 (fi) 1994-11-09
AU673419B2 (en) 1996-11-07
ATE183191T1 (de) 1999-08-15
AU6194994A (en) 1994-11-10
IL109580A0 (en) 1994-08-26
ES2136677T3 (es) 1999-12-01
CA2123052C (en) 2005-04-26
GR3031541T3 (en) 2000-01-31
HU9401408D0 (en) 1994-08-29
KR100333151B1 (ko) 2002-09-04
HUT67574A (en) 1995-04-28

Similar Documents

Publication Publication Date Title
DK0624594T3 (da) Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel
DK0624595T3 (da) Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DK0624596T3 (da) Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DK0610487T3 (da) Nye aminosyrederivater, fremgangsmåde til deres fremstilling og farmaceutiske præparater indeholdende disse forbindelser
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
PT778277E (pt) Derivados heterociclicos substituidos como antagonistas do crf
NO964700D0 (no) Nye aminosyrederivater, fremgangsmåte til deres fremstilling og farmasöytiske blandinger som inneholder disse forbindelser
DK0590271T3 (da) 17beta-aryl- og 17beta-heterocyclyl-5alfa, 14beta-androstan-, androsten- og -androstadienderivater med aktivitet på det kardiovaskulære system, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse
NO924921L (no) Polyaspartamidderivater som adsorbsjonsmiddel for gallesyrer, polyaspartamidderivat lastet med gallesyrer og fremgangsmaater for fremstilling av disse, samt deres anvendelse som legemiddel
DK0648779T3 (da) 11-benzaldoxim-17beta-methoxy-17alfa-methoxymethyl-estradien-derivater, fremgangsmåder til deres fremstilling og lægemidler indeholdende disse forbindelser
DK0632026T3 (da) Alfa-aminosyrederivater, en fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
DK383388A (da) 3-demethyl-4-fluor-mevalonsyrederivater, deres fremstilling, farmaceutiske praeparater deraf, deres anvendelse og mellemprodukter til deres fremstilling
DK0736009T3 (da) N-oxider af 4-arylpiperaziner og 4-arylpiperidiner som antipsykotiske medikamenter
NO301826B1 (no) Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK393785D0 (da) Sulfonyliso(thio)urinstofderivater, fremgangsmaade til fremstilling deraf og deres anvendelse som herbicider
DK0635491T3 (da) (Thia)cycloalkylab indoler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse forbindelser.